Genomic Service Cluster
By building a dedicated genomic-services cluster around Eurofins MWG and creating a European genome technology campus centered at the Eurofins MWG laboratory, Eurofins also aims to foster the codevelopment of DNA/RNA services to the pharmaceutical and analytical industries through collaboration between Eurofins Medigenomix and other Eurofins businesses, combined with the clinical expertise of Eurofins Optimed, the groups’ 60-bed clinical research unit.
“Our aim is to allow both research and commercial customers access to the highest quality DNA testing services for expanding applications in the food, pharma, and environmental fields.”
Medigenomix became part of the Eurofins group in 2001, and since 2005 Eurofins Medigenomix has represented the outsourcing partner of MWG for genomic services. Eurofins acquired an equity stake in MWG during 2004 and now owns some 85% of the company.
“MWG has been fairly quiet with respect to major announcements over the last couple of years, but we have taken this time to develop the best strategy for maximizing the respective expertise of both MWG and Eurofins Medigenomix,” Dr. Poddevin continued. “We believe Eurofins MWG is the perfect vehicle to promote both MWG and Eurofins Medigenomix’ current and future portfolios, and offer clients the highest quality services and products.”
Headquartered in Ebersberg, Germany, Eurofins MWG starts with E20 million in annual brand sales, 150 employees, and manufacturing laboratories in Germany, U.S., and India. Mirroring its parent, Eurofins group, the business aims to double in size every five to six years, both through organic growth and acquisitions.